Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate

Purpose This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH). Methods A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/mL) groups at baseline. Follow-up for PSA was performed at the sixth postoperative month. Baseline and postoperative clinical parameters, functional parameters, PCa incidence, and postoperative changes in PSA were compared between the low- and high-PSA groups. Results The baseline PSA of 1,296 patients (mean age, 69.7±6.8 years) was 4.0±4.1 ng/mL, with 712 patients (55.0%) in the low-PSA group (1.6±0.8 ng/mL), and 584 patients (45.0%) in the high-PSA group (6.9±4.7 ng/mL). Incidental PCa was detected in 82 patients (6.3%), with a similar incidence in the low-PSA (41 patients, 5.9%) and high-PSA (41 patients, 7.0%) groups (P>0.05). At 6 months postoperatively, both groups showed significant improvements in the maximum flow rate, postvoid residual volume, and all domains of the International Prostate Symptom Score (P<0.05). At postoperative 6 months, the PSA level significantly decreased by 66.6%±23.6% in all patients (54.3%±23.9% in the low-PSA group; 79.6%±14.7% in the high-PSA group) (P<0.05), and the PSA levels of 1,264 patients (97.6%) had normalized. Conclusions In patients with elevated PSA presenting with LUTS/BPH, our study demonstrated significant improvements in functional parameters and decreased PSA after HoLEP. The incidental PCa detection rate did not show a statistically significant difference between the low- and high-PSA groups. Timely surgery for LUTS/BPH without delay due to PSA monitoring should be considered.

[1]  Minyong Kang,et al.  Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients , 2020, Prostate international.

[2]  P. Phukan,et al.  Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma , 2020, Journal of Laboratory Physicians.

[3]  F. Chun,et al.  Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study , 2020, World Journal of Urology.

[4]  J. Romero‐Otero,et al.  Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice , 2020, BJU international.

[5]  Seung-June Oh.  Current surgical techniques of enucleation in holmium laser enucleation of the prostate , 2019, Investigative and clinical urology.

[6]  R. Schiavina*,et al.  Preoperative multiparametric prostate magnetic resonance imaging: a safe clinical practice to reduce incidental prostate cancer in Holmium laser enucleation of the prostate , 2019, Central European journal of urology.

[7]  C. Park,et al.  A randomized controlled comparison between periprostatic nerve block and pelvic plexus block at the base and apex of 14-core prostate biopsies , 2019, World Journal of Urology.

[8]  M. Cho,et al.  Self-assessed goal achievement (SAGA) after Holmium laser enucleation of the prostate (HoLEP): Association with patients' postoperative satisfaction , 2018, PloS one.

[9]  Thomas Agoritsas,et al.  Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis , 2018, British Medical Journal.

[10]  U. Capitanio,et al.  Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. , 2018, Urology.

[11]  M. Burger,et al.  HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis , 2018, World Journal of Urology.

[12]  Y. Xu,et al.  Additional value of the ratio of serum total testosterone to total prostate‐specific antigen in the diagnosis of prostate cancer in a Chinese population , 2018, Andrologia.

[13]  F. Hamdy,et al.  Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. , 2018, Cancer epidemiology.

[14]  Seung-June Oh,et al.  Patient satisfaction after holmium laser enucleation of the prostate (HoLEP): A prospective cohort study , 2017, PloS one.

[15]  S. Cho,et al.  A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores , 2017, Journal of Cancer Research and Clinical Oncology.

[16]  Seung-June Oh,et al.  Holmium Laser Enucleation of the Prostate is Safe for Patients Above 80 Years: A Prospective Study , 2016, International neurourology journal.

[17]  Seung-June Oh,et al.  Urodynamic Features and Significant Predictors of Bladder Outlet Obstruction in Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Small Prostate Volume. , 2016, Urology.

[18]  M. Elhilali,et al.  Incidental Prostate Cancer Diagnosis During Holmium Laser Enucleation: Assessment of Predictors, Survival, and Disease Progression. , 2015, Urology.

[19]  A. Unsal,et al.  Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature. , 2014, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[20]  H. Cho,et al.  The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen , 2014, Prostate international.

[21]  Hak Jong Lee,et al.  The future perspectives in transrectal prostate ultrasound guided biopsy , 2014, Prostate international.

[22]  Ho Gyun Park,et al.  Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status , 2014, Korean journal of urology.

[23]  M. A. Salam,et al.  Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer. , 2013, Bangladesh Medical Research Council bulletin.

[24]  Yoosoo Chang,et al.  Association of prostate specific antigen concentration with lifestyle characteristics in Korean men. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[25]  M. Humphreys,et al.  Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate , 2011, International journal of urology : official journal of the Japanese Urological Association.

[26]  B. Helfand,et al.  Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. , 2009, Urology.

[27]  R. Achten,et al.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies , 2009, International Urology and Nephrology.

[28]  C. Roehrborn,et al.  The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia , 2008, International Journal of Impotence Research.

[29]  P. Puppo.  Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma. , 2007, European urology.

[30]  D. Katz,et al.  Health perceptions in patients who undergo screening and workup for prostate cancer. , 2007, Urology.

[31]  R. Paterson,et al.  Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? , 2005, Journal of endourology.

[32]  H. Parmar,et al.  The role of the IPSS (International Prostate Symptoms Score) in predicting acute retention of urine in patients undergoing major joint arthroplasty. , 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[33]  S. Yazıcı,et al.  Detection of Prostate Cancer and Changes in Prostate-Specific Antigen (PSA) Six Months after Surgery for Benign Prostatic Hyperplasia in Patients with Elevated PSA , 2003, Urologia Internationalis.

[34]  J. Hugosson,et al.  Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. , 2003, European urology.

[35]  M. Solomon,et al.  Age specific prostate specific antigen reference ranges: population specific. , 1998, The Journal of urology.